| Document |
Document Title |
|
JPH0873492A |
PURPOSE: To obtain the subject new compounds which are specific azasteroids, having inhibiting actions on testosterone 5α-reductases and useful for treatment, etc., of diseases caused by androgenic actions such as prostatic hypertrophy,...
|
|
JPH0859476A |
PURPOSE: To provide a new saponin compound exhibiting excellent hepatopathy- suppressing action and low side effects and useful as an agent for the treatment of hepatitis. CONSTITUTION: This agent is composed of the compound of formula I...
|
|
JPH08502059A |
PCT No. PCT/HU93/00058 Sec. 371 Date Mar. 23, 1995 Sec. 102(e) Date Mar. 23, 1995 PCT Filed Oct. 1, 1993 PCT Pub. No. WO94/07909 PCT Pub. Date Apr. 14, 1994The invention relates to novel 17 beta -substituted 4-azaandrostane derivatives o...
|
|
JPH0819151B2 |
Compounds of formula (I): (in which: R<1> is a hydrogen atom, an unsubstituted alkyl group, an aryl-substituted alkyl group or a heterocyclic-substituted alkyl group; R<2> is an aryl-substituted alkyl group, a heterocyclic-substituted al...
|
|
JPH07119232B2 |
Described are new 7 beta -substituted 4-aza-5 alpha -cholestan-3-ones and related compounds as 5 alpha -reductase inhibitors.
|
|
JPH07110875B2 |
Disclosed is a new process for producing finasteride which involves reacting the magnesium halide salt of 17β-carboalkoxy-4-aza-5α-androst-1-en-3-one with t-butylamino magnesium halide, present in at least a 2:1 molar ratio to the este...
|
|
JPH07110830B2 |
|
|
JPH07285909A |
PURPOSE: To provide a new phenanthrene derivative having IL-1 inhibiting activity and useful for the treatment of chronic inflammatory diseases. CONSTITUTION: This phenanthrene derivative is a compound selected from the compounds of form...
|
|
JPH0796552B2 |
|
|
JPH0794437B2 |
|
|
JPH07508524A |
(57) [Summary] Since this publication is application data before electronic filing, summary data is not recorded.
|
|
JPH07508290A |
Invented are 17 beta -substituted acyl-4-aza analogues of steroidal synthetic compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5- alpha -reductase. Also invented ...
|
|
JPH07508038A |
PCT No. PCT/US93/04746 Sec. 371 Date Nov. 17, 1994 Sec. 102(e) Date Nov. 17, 1994 PCT Filed May 19, 1993 PCT Pub. No. WO93/23040 PCT Pub. Date Nov. 25, 1993.Compounds of Formula I I wherein Z contains an ether or thioether moeity, are in...
|
|
JPH07508039A |
PCT No. PCT/US93/04771 Sec. 371 Date Nov. 17, 1994 Sec. 102(e) Date Nov. 17, 1994 PCT Filed May 19, 1993 PCT Pub. No. WO93/23041 PCT Pub. Date Nov. 25, 1993Compounds of Formula (I), (I) wherein X is sulfur or oxygen are inhibitors of the...
|
|
JPH07508032A |
PCT No. PCT/US93/04630 Sec. 371 Date Nov. 14, 1994 Sec. 102(e) Date Nov. 14, 1994 PCT Filed May 17, 1993 PCT Pub. No. WO93/23051 PCT Pub. Date Nov. 25, 1993.Described are delta 17 and delta 20 olefinic and saturated 17 Beta-substituted 4...
|
|
JPH07508034A |
PCT No. PCT/US93/04633 Sec. 371 Date Mar. 20, 1995 Sec. 102(e) Date Mar. 20, 1995 PCT Filed May 17, 1993 PCT Pub. No. WO93/23038 PCT Pub. Date Nov. 25, 1993Novel amino substituted 4-azasteroid 5 alpha -reductase inhibitors of formula (I)...
|
|
JPH07508033A |
Described are new 17 beta -ester, amide and ketone 4-aza-5a-androstan-3-ones and related compounds and their use as 5a-reductase inhibitors for treatment of benign prostatic hyperplasia and other hyperandrogenetic related disorders.
|
|
JPH07508035A |
PCT No. PCT/US93/04634 Sec. 371 Date Mar. 1, 1995 Sec. 102(e) Date Mar. 1, 1995 PCT Filed May 17, 1993 PCT Pub. No. WO93/23048 PCT Pub. Date Nov. 25, 1993 (I) (a) (b) alpha -reductase inhibitors of formula (I), wherein A is (a), (b) or (...
|
|
JPH07206759A |
PURPOSE: To provide a new compd. useful for preventing and treating a 5α-reductase inhibitor, benign prostatic hypertrophy, acne, female hirsutism, male alopecia, androgenic hormone alopecia, prostatism and prostatic cancer. CONSTITUTIO...
|
|
JPH07506575A |
Inhibitors of testosterone 5 alpha -reductase activity, for example those of formula: wherein novel substituents are provided at the R4, R6, R7, R17 alpha and/or R17 beta positions are useful for the treatment of diseases whose progress ...
|
|
JPH07149651A |
PURPOSE: To obtain an inexpensive inhibitor of bone resorption or cartilage degradation containing wortmannin and its analog as active ingredients and free from adverse effects. CONSTITUTION: This inhibitor contains a compound selected f...
|
|
JPH0730111B2 |
A novel process for the preparation of a 16-imino-17-aza-steroid of the formula I wherein A is selected from the group consisting of hydrogen and tritium comprising reacting a compound of the formula II wherein A has the above definition...
|
|
JPH0725791B2 |
A process for dehydrogenating a compound of the formula which comprises reacting the compound with a silylating agent in the presence of a quinone to introduce a DELTA <1> double bond. Novel intermediates are compounds of the formula whe...
|
|
JPH07502511A |
PCT No. PCT/US92/11109 Sec. 371 Date Aug. 15, 1994 Sec. 102(e) Date Aug. 15, 1994 PCT Filed Dec. 18, 1992 PCT Pub. No. WO/9313124 PCT Pub. Date Jul. 8, 1993The present invention relates to certain substituted 17 beta -substituted carbony...
|
|
JPH0717674B2 |
A novel single-pot trialkylsilyl trifluoromethanesulfonate (R3Si-OTf) mediated process produces derivatives of 4-aza 3-keto steroids at the alpha -methylenic carbon through electrophilic substitution. These derivatives are useful in the ...
|
|
JPH0714959B2 |
A process for preparing compounds of the formula which comprises reacting an imidazolide of the formula with an amine of the formula NHR4R5 in the presence of a grinard reagent to form a compound of formula I or reacting an imidazolide o...
|
|
JPH06511498A |
A compound of formula (I): (I) wherein R is a hydrogen atom or a C1-C4 alkyl group; A is a single bond or a straight or branched C1-C6 alkylene chain; R1 is a hydrogen atom or a C1-C6 alkyl group; R2 is a C1-C6 alkyl group, a C5-C7 cyclo...
|
|
JPH06511496A |
(57) [Summary] Since this publication is application data before electronic filing, summary data is not recorded.
|
|
JPH06340689A |
PURPOSE: To obtain the subject new compound useful as a plant growth regulator capable of manifesting excellent persistent plant growth regulating action on various plants in the agrocultural and horticultural fields. CONSTITUTION: This ...
|
|
JPH0699469B2 |
Described is a new intermediate and new process for preparing 3-oxo-4-aza-androst-1-ene 17 beta -ketones. The process involves converting the corresponding 17 beta -alkyl carboxylate to the N-methoxy-N-methyl carboxamide and reacting thi...
|
|
JPH0696591B2 |
This invention pertains to novel 3-substituted-aminomethyl-3-substituted-oxy-17a-methyl-17a-l
ower-alkyl -17a-aza-D-homo-5-alpha-androstane compounds useful as muscle relaxants, methods for preparing such compounds, and methods for admin...
|
|
JPH06316591A |
PURPOSE: To obtain the new compound as a steroidal reductase inhibitor comprising a 17β-polyaroyl-4-aza-5α-androst-1-en-3-one compound for the treatment of acne, seborrhea, hirsutism, prostatic hypertrophy or the like. CONSTITUTION: An...
|
|
JPH06293793A |
PURPOSE: To profitably obtain the subject compound having a 5α-reductase- inhibiting action by a simple operation comprising reacting a specific carboxylic acid compound with a specified amine compound in the presence of a sulfonyl comp...
|
|
JPH0651718B2 |
A process for introducing a 1,2 double bond into a compound of the formula which comprises the process of (a) treating the compound of formula I with oxalyl chloride; (b) brominating the product of step (a) followed by in situ dehydrobro...
|
|
JPH0649674B2 |
A novel, facile, and specific process for alpha -iodinating or alpha -brominating the alpha -methylenic carbon of a straight chain, branched chain, or cyclic secondary amide, such as a lactam or an azasteroid, comprises reacting the amid...
|
|
JPH0641478B2 |
|
|
JPH0637515B2 |
Disclosed is a new process for making 17-beta branched alkanoyl-3-oxo-4-aza-5- alpha -androst-1-enes, agents for treating benign prostatic hypertrophy (BPH), by reacting methyl 3-oxo-4-aza-5- alpha -androst-1-ene-17-beta carboxylate with...
|
|
JPH06100587A |
PURPOSE: To obtain new 7β-substd.-4-aza-5α-androstan-3-ones as 5α-reductase inhibitors useful in the treatment of benign prostatic hyperplasia, acne, male sex type alopecia, prostatitis, etc., and in the prophylaxis and treatment of p...
|
|
JPH0617283B2 |
An agent for increasing the yield of a cereal comprising at least one selected from the group consisting of a brassinolide derivative of the formulae: and wherein R is hydrogen or acetyl and a method for increasing the yield of a cereal ...
|
|
JPH06501272A |
The preparation of a compound of formula (I) wherein X is oxygen or sulphur; R1 is hydrogen or C1-C6 alkyl; each of R2 and R3 is, independently, hydrogen, C1-C6 alkyl, C5 or C6 cycloalkyl or C6-C9 cycloalkylalkyl; R4 is hydrogen, C1-C6 a...
|
|
JPH05255383A |
PURPOSE: To prepare a compd. for antiandrogen agents or the like composed of 17β-N-substituted adamantyl/norbonanyl carbamoyl-4-aza-5α-androsto-1-en-3- one or the like and inhibiting 5α-reductase. CONSTITUTION: 17β-(carbomethoxy)-4-a...
|
|
JPH05255382A |
PURPOSE: To prepare a medicament contg. a new testosterone 5α-reductase inhibiting agent and useful for the prevention of human male prostatic carcino ma for men free from the symptom of prostatic carcinoma. CONSTITUTION: The objective ...
|
|
JPH05213989A |
PURPOSE: To obtain a 17β-substd. aza-androstane deriv. having 5α-reductase inhibiting activity and used in the treatment of prostatic hypertrophy, prostatic cancer, seborrhea, acne, rough hair symptom, etc., by allowing a specified aza...
|
|
JPH05213988A |
PURPOSE: To obtain a new sesterterpenoid exhibiting in vitro proliferation- inhibiting activity to mouse lymphogenous leukemic cell P388, reduced in side effects and expected in utilization as an antitumo agent by extracting and purifyin...
|
|
JPH05194585A |
PURPOSE: To obtain the subject compound having excellent antimicrobial, antifungal and antitumor actions. CONSTITUTION: The objective compound expressed by the formula. As physico- chemical properties of the compound expressed by the for...
|
|
JPH05504577A |
The present invention relates to novel substituted 15-oxa-, 15-thia-, and 15-aza- dihydrolanosterols, to pharmaceutical compositions containing such compounds, and to methods of using these compounds to suppress the activity of 3-hydroxy...
|
|
JPH0541638B2 |
17 beta -N-monosubstituted carbamoyl or 17 beta -acyl-4-aza-5 alpha -androst-1-en-3-ones of the formula: in which R is hydrogen, methyl or ethyl; R<2> is a C1-12 straight or branched alkyl radical or a monocyclic aryl optionally containi...
|
|
JPH05148294A |
PURPOSE: To obtain the subject new steroid derivative useful as a bisosynthesis inhibitor of esterogens, a therapeutic agent for diseases such as mammary cancer, uterine cancer, etc., caused by excessive estrogen, etc., having a specific...
|
|
JPH0533712B2 |
|
|
JPH0477759B2 |
|
